

# WEST

[Help](#)    [Logout](#)    [Interrupt](#)

[Main Menu](#) | [Search Form](#) | [Posting Counts](#) | [Show S Numbers](#) | [Edit S Numbers](#) | [Preferences](#) | [Cases](#)

---

## Search Results -

Terms	Documents
von willebrand complex and L8	178035

---

**Database:**  US Patents Full-Text Database  US Pre-Grant Publication Full-Text Database  
 JPO Abstracts Database  EPO Abstracts Database  
 Derwent World Patents Index  IBM Technical Disclosure Bulletins

**Search:**  Refine Search

## Search History

---

**DATE:** Friday, December 05, 2003    [Printable Copy](#)    [Create Case](#)

**Set Name** Query  
side by side

**Hit Count** Set Name  
result set

*DB=USPT; PLUR=YES; OP=OR*

<u>L9</u>	von willebrand complex and L8	178035	<u>L9</u>
<u>L8</u>	I3 and cation exchange chromatography	396590	<u>L8</u>
<u>L7</u>	preparation and L6	46853	<u>L7</u>
<u>L6</u>	virus safe and L5	66535	<u>L6</u>
<u>L5</u>	I3 and L4	148883	<u>L5</u>
<u>L4</u>	cation exchange	301373	<u>L4</u>
<u>L3</u>	factor VIII adj2 von Willebrand factor complex	939911	<u>L3</u>
<u>L2</u>	6605222.pn.	1	<u>L2</u>
<u>L1</u>	6228613.pn.	1	<u>L1</u>

END OF SEARCH HISTORY

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1653hxp

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:35:15 ON 05 DEC 2003

=> file medline, uspatful, dgene, embase, wpids, fsta,biosis,  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 0.63 0.63

FILE 'MEDLINE' ENTERED AT 11:37:05 ON 05 DEC 2003

FILE 'USPATFULL' ENTERED AT 11:37:05 ON 05 DEC 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 11:37:05 ON 05 DEC 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 11:37:05 ON 05 DEC 2003  
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 11:37:05 ON 05 DEC 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 11:37:05 ON 05 DEC 2003  
COPYRIGHT (C) 2003 International Food Information Service

FILE 'BIOSIS' ENTERED AT 11:37:05 ON 05 DEC 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

=> s factor VIII and von Willebrand factor complex  
L1 150 FACTOR VIII AND VON WILLEBRAND FACTOR COMPLEX

=> s factor VIII/vWF-complex  
'VWF-COMPLEX' IS NOT A VALID FIELD CODE  
L2 0 FACTOR VIII/VWF-COMPLEX

=> s factor VIII ()von Willibrand Factor () complex  
L3 0 FACTOR VIII (W) VON WILLIBRAND FACTOR (W) COMPLEX

=> s l1 and cation exchange chromatography  
L4 1 L1 AND CATION EXCHANGE CHROMATOGRAPHY

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 1 USPATFULL on STN  
TI Method for producing a **factor VIII/von**  
**Willebrand factor complex**  
AB The invention relates to a method for the production of **factor**  
**VIII:C/von Willebrand factor**  
**complex** from plasma or a plasma fraction by chromatography in a  
cation exchanger, wherein the **factor VIII:C/von**  
**Willebrand factor complex** is  
obtained with at least 300 times the purity of the plasma and the yield  
of **factor VIII:C** and the von Willebrand factor is at  
least 50% in relation to cryoprecipitates or analogous plasma fractions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:215997 USPATFULL

TITLE: Method for producing a **factor VIII/von**  
**Willebrand factor complex**

INVENTOR(S): Linnau, Yendra, Vienna, AUSTRIA

Schoenhofer, Wolfgang, St. Poelten, AUSTRIA

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, AUSTRIA (non-U.S.  
corporation)

NUMBER KIND DATE

----- ----- -----

PATENT INFORMATION:	US 6605222	B1	20030812
	WO 9943712		19990902
APPLICATION INFO.:	US 2001-623245	20010319	(9)
	WO 1999-AT48		19990225

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1998-866	19980520
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Therkorn, Ernest G.	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP, Fedrick, Michael F.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	203	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=> d his

(FILE 'HOME' ENTERED AT 11:35:15 ON 05 DEC 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT  
11:37:05 ON 05 DEC 2003

L1        150 S FACTOR VIII AND VON WILLEBRAND FACTOR COMPLEX  
 L2        0 S FACTOR VIII/VWF-COMPLEX  
 L3        0 S FACTOR VIII ()VON WILLIBRAND FACTOR () COMPLEX  
 L4        1 S L1 AND CATION EXCHANGE CHROMATOGRAPHY

=> s low molecular weight vWF multimer  
 L5        0 LOW MOLECULAR WEIGHT VWF MULTIMER

=> s l1 and virus-safe  
 L6        1 L1 AND VIRUS-SAFE

=> d l6 ti abs ibib tot

L6        ANSWER 1 OF 1 USPATFULL on STN  
 TI        Stable factor VIII/von Willebrand  
           factor complex  
 AB        There are disclosed a stable factor VIII  
           /vWF-complex, particularly comprising high-molecular vWF multimers,  
           being free from low-molecular vWF molecules and from proteolytic vWF  
           degradation products, as well as a method of producing this complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:67424	USPATFULL
TITLE:	Stable factor VIII/von Willebrand factor complex	
INVENTOR(S):	Fischer, Bernhard, Vienna, Austria Mitterer, Artur, Mannsdorf, Austria Dorner, Friedrich, Vienna, Austria Eibl, Johann, Vienna, Austria	
PATENT ASSIGNEE(S):	Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)	

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228613	B1	20010508
	WO 9734930		19970925
APPLICATION INFO.:	US 1998-142768	19981106	(9)
	WO 1997-AT55	19970313	
		19981106	PCT 371 date

19981106 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-494	19960315
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Carlson, Karen Cochrane	
ASSISTANT EXAMINER:	Robinson, Hope A.	
LEGAL REPRESENTATIVE:	Heller Ehrman White & McAuliffe	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 9 Drawing Page(s)	
LINE COUNT:	1098	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=> d his

(FILE 'HOME' ENTERED AT 11:35:15 ON 05 DEC 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT  
11:37:05 ON 05 DEC 2003

L1        150 S FACTOR VIII AND VON WILLEBRAND FACTOR COMPLEX  
L2        0 S FACTOR VIII/VWF-COMPLEX  
L3        0 S FACTOR VIII ()VON WILLIBRAND FACTOR () COMPLEX  
L4        1 S L1 AND CATION EXCHANGE CHROMATOGRAPHY  
L5        0 S LOW MOLECULAR WEIGHT VWF MULTIMER  
L6        1 S L1 AND VIRUS-SAFE

=> s l1 and preparation

L7        33 L1 AND PREPARATION

=> s l7 and cation exchange chromatography

L8        1 L7 AND CATION EXCHANGE CHROMATOGRAPHY

=> d l8 ti abs ibib tot

L8        ANSWER 1 OF 1 USPATFULL on STN

TI        Method for producing a **factor VIII/von  
Willebrand factor complex**

AB        The invention relates to a method for the production of **factor  
VIII:C/von Willebrand factor  
complex** from plasma or a plasma fraction by chromatography in a  
cation exchanger, wherein the **factor VIII:C/von Willebrand factor complex** is  
obtained with at least 300 times the purity of the plasma and the yield  
of **factor VIII:C** and the von Willebrand factor is at  
least 50% in relation to cryoprecipitates or analogous plasma fractions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:215997 USPATFULL

TITLE: Method for producing a **factor VIII/von Willebrand factor complex**

INVENTOR(S): Linnau, Yendra, Vienna, AUSTRIA

Schoenhofer, Wolfgang, St. Poelten, AUSTRIA

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, AUSTRIA (non-U.S.  
corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6605222	B1	20030812	<i>bud date</i>
	WO 9943712		19990902	

APPLICATION INFO.: US 2001-623245 20010319 (9)  
                       WO 1999-AT48 19990225

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1998-866	19980520
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Therkorn, Ernest G.	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP, Fedrick, Michael F.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	203	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=> d his

(FILE 'HOME' ENTERED AT 11:35:15 ON 05 DEC 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT  
   11:37:05 ON 05 DEC 2003

L1       150 S FACTOR VIII AND VON WILLEBRAND FACTOR COMPLEX  
  L2       0 S FACTOR VIII/VWF-COMPLEX  
  L3       0 S FACTOR VIII ()VON WILLIBRAND FACTOR () COMPLEX  
  L4       1 S L1 AND CATION EXCHANGE CHROMATOGRAPHY  
  L5       0 S LOW MOLECULAR WEIGHT VWF MULTIMER  
  L6       1 S L1 AND VIRUS-SAFE  
  L7       33 S L1 AND PREPARATION  
  L8       1 S L7 AND CATION EXCHANGE CHROMATOGRAPHY

=> d l7 ti abs ibib 1-5

L7       ANSWER 1 OF 33      MEDLINE on STN  
  TI      Isolation of the factor VIII-von  
           Willebrand factor complex directly from plasma  
           by gel filtration.  
  AB      A high capacity gel filtration system was developed with the purpose of  
           isolating factor VIII (FVIII) and von Willebrand  
           factor (vWF) directly from plasma in significantly higher yields than  
           obtained by cryoprecipitation, the technique most commonly used to recover  
           FVIII-vWF from human plasma. After laboratory-scale gel filtration of  
           plasma, a FVIII-containing fraction was collected containing about 90% of  
           FVIII in the applied plasma and with almost tenfold higher purity than  
           that obtained by cryoprecipitation. The gel filtration step has been  
           scaled up for use as the initial step in the manufacturing process for a  
           FVIII preparation (Nordiate).

ACCESSION NUMBER: 1999007008 MEDLINE

DOCUMENT NUMBER: 99007008 PubMed ID: 9792522

TITLE: Isolation of the factor VIII-  
       von Willebrand factor

complex directly from plasma by gel filtration.

AUTHOR: Kaersgaard P; Barington K A

CORPORATE SOURCE: HemaSure Denmark A/S, Gentofte.

SOURCE: JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND  
       APPLICATIONS, (1998 Sep 18) 715 (2) 357-67.

Journal code: 9714109. ISSN: 1387-2273.

PUB. COUNTRY: Netherlands

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199812

ENTRY DATE: Entered STN: 19990115

*bondi date*

Last Updated on STN: 19990115  
Entered Medline: 19981218

L7 ANSWER 2 OF 33 MEDLINE on STN  
TI Concentrated DDAVP: further improvement in the management of mild factor VIII deficiencies.  
AB This study was carried out to evaluate the pharmacological efficacy of a new concentrated 1 Deamino - (8-D-arginine) -vasopressin (DDAVP) preparation. Concentrated DDAVP (C-DDAVP), (40 micrograms/mL) was given subcutaneously (s.c.) in hemophilia and von Willebrand Disease (vWD), and the response was evaluated in terms of factor VIII/vWF (VIII/von Willebrand Factor complex). This response was also compared to that obtained using the currently available commercial preparation (4 micrograms/mL) given either s.c. or intravenously (i.v.). The maximal f. VIII response after s.c. C-DDAVP was reached one hour after the injection (means: 3.5 times the resting values) with an average decline of 15% at two hours. The response to s.c. C-DDAVP in patients with hemophilia was slightly better than that obtained with the diluted brand, but the difference did not reach any statistical significance even when the schedules were compared in the same patients. In type I (platelet normal subtype) vWD, a higher response in terms of factor VIII :C increase in comparison with hemophiliacs was obtained. Both Ristocetin co-factor activity (Ricof) and bleeding time responded to this vasopressin analogue, when administered subcutaneously.

ACCESSION NUMBER: 88127637 MEDLINE  
DOCUMENT NUMBER: 88127637 PubMed ID: 3124287  
TITLE: Concentrated DDAVP: further improvement in the management of mild factor VIII deficiencies.  
AUTHOR: Ghirardini A; Mariani G; Iacopino G; Tirindelli M C; Solinas S; Moretti T  
CORPORATE SOURCE: Department of Human Biopathology, Hematology, University of Roma, La Sapienza, Italy.  
SOURCE: THROMBOSIS AND HAEMOSTASIS, (1987 Oct 28) 58 (3) 896-8.  
JOURNAL code: 7608063. ISSN: 0340-6245.  
PUB. COUNTRY: GERMANY, WEST: Germany, Federal Republic of  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 198803  
ENTRY DATE: Entered STN: 19900308  
Last Updated on STN: 19990129  
Entered Medline: 19880316

L7 ANSWER 3 OF 33 MEDLINE on STN  
TI Effect of phospholipid on factor VIII coagulant activity and coagulant antigen.  
AB Incubation of purified factor VIII/von Willebrand factor complex or plasma with certain phospholipid preparation induced a two to threefold increase in apparent factor VIII activity, while a slight decrease of factor VIII coagulant antigen was observed. Between six or eightfold activity increases occurred when 10-3 units/ml of thrombin was present during the incubation. When the phospholipid was added first and the thrombin added 30 minutes later a twofold increase in apparent factor VIII activity occurred during the first part and this activity was then increased threefold further after the addition of thrombin. In separate experiments using gel filtration on Sepharose 2B, association of factor VIII activity to phospholipid vesicles could be demonstrated. This phospholipid bound factor VIII could be activated by thrombin. The relationship between these observations and the formation of factor X activating complex is discussed.

ACCESSION NUMBER: 83303023 MEDLINE

DOCUMENT NUMBER: 83303023 PubMed ID: 6412394  
TITLE: Effect of phospholipid on **factor VIII**  
coagulant activity and coagulant antigen.  
AUTHOR: Broden K; Brown J E; Carton C; Andersson L O  
SOURCE: THROMBOSIS RESEARCH, (1983 Jun 15) 30 (6) 651-60.  
Journal code: 0326377. ISSN: 0049-3848.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 198310  
ENTRY DATE: Entered STN: 19900319  
Last Updated on STN: 19900319  
Entered Medline: 19831028

L7 ANSWER 4 OF 33 USPATFULL on STN  
TI Method and pharmaceutical composition for preventing and/or treating  
systemic inflammatory response syndrome  
AB A partial inhibitor of **factor VIII** such as a  
monoclonal antibody is useful for preventing and/or treating a disease  
selected from the group consisting of systemic inflammatory response  
syndrome, sepsis, septic shock, thrombus formation in the  
micro-vasculature and disseminated intravascular coagulation in a mammal  
by partially inhibiting thrombin formation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2003:250483 USPATFULL  
TITLE: Method and pharmaceutical composition for preventing  
and/or treating systemic inflammatory response syndrome  
INVENTOR(S): Saint-Remy, Jean-Marie R., Grez-Doiceau, BELGIUM  
Jacquemin, Marc G., Sart-Bernard, BELGIUM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175268	A1	20030918
APPLICATION INFO.:	US 2002-44569	A1	20020111 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Lee, Mann, Smith, McWilliams, Sweeney, & Ohlson, P.O. Box 2786, Chicago, IL, 60690-2786		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Page(s)		
LINE COUNT:	1430		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 33 USPATFULL on STN  
TI Method for producing a **factor VIII/von  
Willebrand factor complex**  
AB The invention relates to a method for the production of **factor  
VIII:C/von Willebrand factor**  
**complex** from plasma or a plasma fraction by chromatography in a  
cation exchanger, wherein the **factor VIII:C/von Willebrand factor complex** is  
obtained with at least 300 times the purity of the plasma and the yield  
of **factor VIII:C** and the von Willebrand factor is at  
least 50% in relation to cryoprecipitates or analogous plasma fractions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2003:215997 USPATFULL  
TITLE: Method for producing a **factor VIII/von Willebrand factor complex**  
INVENTOR(S): Linnau, Yendra, Vienna, AUSTRIA

PATENT ASSIGNEE(S) : Schoenhofer, Wolfgang, St. Poelten, AUSTRIA  
Baxter Aktiengesellschaft, Vienna, AUSTRIA (non-U.S.  
corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6605222	B1	20030812	<i>bud slate</i>
	WO 9943712		19990902	
APPLICATION INFO.:	US 2001-623245		20010319 (9)	
	WO 1999-AT48		19990225	

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1998-866	19980520
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Therkorn, Ernest G.	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP, Fedrick, Michael F.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	203	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		